Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal bioavailability and bioequivalence Bridging Study Comparing ACER-001 with BUPHENYL in Healthy Subjects for treatment of urea-cycle-disorders

Trial Profile

A Pivotal bioavailability and bioequivalence Bridging Study Comparing ACER-001 with BUPHENYL in Healthy Subjects for treatment of urea-cycle-disorders

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 27 Dec 2022 According to an Acer Therapeutics media release, the U.S. Food and Drug Administration (FDA) has approved OLPRUVA™ (sodium phenylbutyrate) for oral suspension in the U.S. for the treatment of certain patients living with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS), based on data from this and other trials.
  • 28 Jul 2022 According to an Acer Therapeutics media release, the U.S. Food and Drug Administration (FDA) has accepted resubmitted New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with urea cycle disorders (UCDs) and designated the NDA as a Class 2 resubmission. The FDA set a Prescription Drug User Fee Act (PDUFA) target action date of January 15, 2023.
  • 18 Jul 2022 According to an Acer Therapeutics media release, additional existing nonclinical information as requested by the FDA in the CRL as well as labeling and other routine updates to the original NDA, were provided in the resubmission of the NDA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top